secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001759425-26-000036
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum Q1 net sales $159.9M, raises FY guidance to $660-680M; volixibat & brelovitug meet primary endpoints
--------------------------------------------------------------------------------

- Q1 2026 net product sales $159.9M, up 43% YoY; LIVMARLI $113.8M (+55%), Bile Acid Medicines $46.1M (+20%).
- Full-year 2026 net product sales guidance raised to $660-680M from prior range.
- Volixibat VISTAS Phase 2b in PSC met primary endpoint; NDA submission expected H2 2026.
- Brelovitug AZURE-1 Phase 2b in HDV met primary endpoint; Phase 3 enrollment complete, topline H2 2026.
- In-licensed zilurgisertib for FOP from Incyte for $16M upfront; FDA Priority Review, PDUFA Sept 26, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000175942526000036/0001759425-26-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000175942526000036/mirm-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001759425-26-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer